Helmy M. Guirgis, MD, PhD

Research Reports

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations

06/18/2019

Helmy M. Guirgis , MD, PhD;

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...

...

06/18/2019

Journal of Clinical Pathways

Research Reports

Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer

12/15/2021

Helmy M. Guirgis , MD, PhD;

Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.

Helmy M Guirgis, MD, PhD, aimed...

12/15/2021

Journal of Clinical Pathways